503649341 01/14/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT3695976 Stylesheet Version v1.2

SUBMISSION TYPE: NEW ASSIGNMENT NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BRIAN N SWANSON	11/10/2015
GIANLUCA PIROZZI	10/23/2015
LEDA MANNENT	10/23/2015

RECEIVING PARTY DATA

Name:	SANOFI
Street Address:	54 RUE LA BOETIE
City:	PARIS
State/Country:	FRANCE
Postal Code:	75008

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14940431

CORRESPONDENCE DATA

Fax Number: (908)981-7830

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 908-981-6998

Email: GlobalPatent.eFlow@sanofi.com

Correspondent Name: ROBIN J. INMAN


Address Line 1: 55 CORPORATE DRIVE Address Line 2: MAIL CODE: 55A-505A

Address Line 4: BRIDGEWATER, NEW JERSEY 08807

ATTORNEY DOCKET NUMBER: US2014/094 US NP **NAME OF SUBMITTER: ROBIN J. INMAN** SIGNATURE: /ROBIN J. INMAN/ **DATE SIGNED:** 01/14/2016

Total Attachments: 10

source=US2014-094USPSP_ExecASGN_AllInventors#page1.tif source=US2014-094USPSP_ExecASGN_AllInventors#page2.tif source=US2014-094USPSP ExecASGN AllInventors#page3.tif



ASSIGNMENT AND AGREEMENT

FOR VALUE RECEIVED and intending to be legally bound, We, the undersigned joint inventors (Assignors), sell, assign and transfer to **SANOFI** (Assignee), 54 rue La Boétie, 75008 Paris, France, and its successors, assigns and legal representatives, our entire and exclusive right, title and interest in and to our invention and any improvements thereon, for all countries of the world, relating in and to the below US priority applications, assigned Sanofi Docket No. **US2014/094** and entitled

METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST

and for all patent applications which claim priority to, or are derived from, said priority applications:

US Provisional Application No. 62/080,092; Filed: November 14, 2014;

US Provisional Application No. 62/083,821; Filed: November 24, 2014;

US Provisional Application No. 62/158,832; Filed: May 8, 2015;

US Provisional Application No. 62/199,305; Filed: July 31, 2015;

and

European Application No. EP15306632.9; Filed: October 14, 2015;

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said United States application, and under any and all Letters Patent which may be granted therefor, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including, without limitation, continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, reexaminations, pipelines and extensions, and governmental exclusivity rights of the same; and I hereby authorize and request the USPTO and any foreign patent authority or office whose duty it is to issue patents on applications or priorities as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment.

We state that we are original inventors of the claimed invention and authorize the filing of a patent application for the claimed invention.

We authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

We agree that, when requested, we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, testify in any legal proceedings, and do all acts which may be necessary, desirable or convenient for securing, maintaining, and enforcing patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

We covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that we have full right to convey the same as herein expressed and that we will not enter into any assignment, contract, or understanding in conflict herewith.

We hereby acknowledge that any willful false statements made in this assignment are punishable by fine or imprisonment, or both, under Title 18, United States code §1001.

	on this day of	, 2015.
(City, State and N Signature: Inventor's Name: Mailing Address:		
Witnessed by:		
Signature:	Signature:	
Name:	Name:	

Signed a	at	o	n this	day of	, 2015.
	(City, State and Na				
	Signature: Inventor's Name: Mailing Address:	GIANLUCA PIRC c/o Sanofi, 55 Bridgewater, N	Corporate	Drive, Mail Coo US	de: 55A-505A
Witness	ed by:				
Signatu	re:		Signatu	re:	
Name:			Name:		
<u> </u>	Bridgewater (City, State and Na Signature: nventor's Name: Mailing Address:	Brian N. SWAN	n. Su ISON Corporate	Drive, Mail Coo	ember, 2015. de: 55A-505A
Witness Signatur Name:	ed by: Te: <u>Maryll</u> Amanda E	E. Jones	Signatu Name:	re: <u>Mudy</u> Trudy.	- Dillon Diccon

ASSIGNMENT AND AGREEMENT

FOR VALUE RECEIVED and intending to be legally bound, We, the undersigned joint inventors (Assignors), sell, assign and transfer to **SANOFI** (Assignee), 54 rue La Boétie, 75008 Paris, France, and its successors, assigns and legal representatives, our entire and exclusive right, title and interest in and to our invention and any improvements thereon, for all countries of the world, relating in and to the below US priority applications, assigned Sanofi Docket No. **US2014/094** and entitled

METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST

and for all patent applications which claim priority to, or are derived from, said priority applications:

US Provisional Application No. 62/080,092; Filed: November 14, 2014;

US Provisional Application No. 62/083,821; Filed: November 24, 2014;

US Provisional Application No. 62/158,832; Filed: May 8, 2015;

US Provisional Application No. 62/199,305; Filed: July 31, 2015;

and

European Application No. EP15306632.9; Filed: October 14, 2015;

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said United States application, and under any and all Letters Patent which may be granted therefor, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including, without limitation, continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, reexaminations, pipelines and extensions, and governmental exclusivity rights of the same; and I hereby authorize and request the USPTO and any foreign patent authority or office whose duty it is to issue patents on applications or priorities as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment.

We state that we are original inventors of the claimed invention and authorize the filing of a patent application for the claimed invention.

We authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

We agree that, when requested, we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, testify in any legal proceedings, and do all acts which may be necessary, desirable or convenient for securing, maintaining, and enforcing patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

We covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that we have full right to convey the same as herein expressed and that we will not enter into any assignment, contract, or understanding in conflict herewith.

We hereby acknowledge that any willful false statements made in this assignment are punishable by fine or imprisonment, or both, under Title 18, United States code §1001.

	on this day of	, 2015.
(City, State and N	Nation)	
Signature:		
Inventor's Name:		
Mailing Address:	c/o Sanofi, 54 rue La Boétie	
	75008 Paris, France	
Vitnessed by:		
vitilessed by.		
iignature:	Signature:	
Name:	Name:	

Signed at Bridgewater (City, State and Na Signature: Inventor's Name: Mailing Address:	GIANLUCA PIROZZI c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A Bridgewater, NJ 08807 US
Witnessed by: Signature:	Caffor Signature: All Organ
Name: Marisa	lifter Name: <u>Cliff Ungaro</u>
Signed at (City, State and Na	on this day of, 2015. ation)
Signature: Inventor's Name: Mailing Address:	BRIAN N. SWANSON c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A Bridgewater, NJ 08807 US
Witnessed by:	
Signature:	Signature:
Name:	Name:

ASSIGNMENT AND AGREEMENT

FOR VALUE RECEIVED and intending to be legally bound, We, the undersigned joint inventors (Assignors), sell, assign and transfer to **SANOFI** (Assignee), 54 rue La Boétie, 75008 Paris, France, and its successors, assigns and legal representatives, our entire and exclusive right, title and interest in and to our invention and any improvements thereon, for all countries of the world, relating in and to the below US priority applications, assigned Sanofi Docket No. **US2014/094** and entitled

METHODS FOR TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING AN IL-4R ANTAGONIST

and for all patent applications which claim priority to, or are derived from, said priority applications:

US Provisional Application No. 62/080,092; Filed: November 14, 2014;

US Provisional Application No. 62/083,821; Filed: November 24, 2014;

US Provisional Application No. 62/158,832; Filed: May 8, 2015;

US Provisional Application No. 62/199,305; Filed: July 31, 2015;

and

European Application No. EP15306632.9; Filed: October 14, 2015;

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said United States application, and under any and all Letters Patent which may be granted therefor, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including, without limitation, continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, reexaminations, pipelines and extensions, and governmental exclusivity rights of the same; and I hereby authorize and request the USPTO and any foreign patent authority or office whose duty it is to issue patents on applications or priorities as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment.

We state that we are original inventors of the claimed invention and authorize the filing of a patent application for the claimed invention.

Witnessed by:

We authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

We agree that, when requested, we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, testify in any legal proceedings, and do all acts which may be necessary, desirable or convenient for securing, maintaining, and enforcing patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

We covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that we have full right to convey the same as herein expressed and that we will not enter into any assignment, contract, or understanding in conflict herewith.

We hereby acknowledge that any willful false statements made in this assignment are punishable by fine or imprisonment, or both, under Title 18, United States code §1001.

Signed at Paris Fru	ance on this 23 day of October, 2	2015.
(City, State and N	lation)	
Signature: Inventor's Name: Mailing Address:	LEDA MANNENT c/o Sanofi, 54 rue La Boétie	
	75008 Paris, France	

Signature: ______ Signature: ______

Name: HORSIN-ZIEGEE Name: ROLLET GONNEL Preducque

Page 3		Attorney Docket No. US2U14/U94US			
Signed at	on th	nis day of	<i></i>	2015.	
(City, State and N	Nation)	, , , , , , , , , , , , , , , , , , , ,			
Signature: Inventor's Name: Mailing Address:	GIANLUCA PIROZZI	rporate Drive, Mai	 I Code: 55A-505A		
Witnessed by:					
Signature:		Signature:			
Name:		Name:			
Signed at	on th	iis day of		2015.	
(City, State and N					
	BRIAN N. SWANSOI c/o Sanofi, 55 Co Bridgewater, NJ	rporate Drive, Mai	— I Code: 55A-505A		
Witnessed by:					
Signature:		Signature:		· · · · · · · · · · · · · · · · · · ·	
Name:		Name:	***************************************		

RECORDED: 01/14/2016